Abstract

The detection of neuronal surface protein autoantibody-related disorders has contributed to several changes in our understanding of central nervous system autoimmunity. The clinical presentation of these disorders may be associated (or not) with tumors, and often patients develop an inexplicable onset of epilepsy, catatonic or autistic features, or memory and cognitive dysfunctions. The autoantigens in such cases have critical roles in synaptic transmission and plasticity, memory function, and process learning. For months, patients with such antibodies may be comatose or encephalopathic and yet completely recover with palliative care and immunotherapies. This paper reviews several targets of neuronal antibodies as biomarkers in seizure disorders, focusing mainly on autoantibodies, which target the extracellular domains of membrane proteins, namely leucine-rich glioma-inactivated-1 (LGI1), contactin-associated protein-like 2 (CASPR2), the N-methyl-D-aspartate receptor (NMDAR), γ-aminobutyric acid receptor-B (GABABR), the glycine receptor (GlyR), and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). In order to restore health status, limit hospitalization, and optimize results, testing these antibodies should be done locally, using internationally certified procedures for a precise and rapid diagnosis, with the possibility of initiating therapy as soon as possible.

Highlights

  • Over the last decade, contrary to established knowledge, a series of autoantibody-mediated seizure-associated disorders have been identified

  • Facio-brachial dystonic seizures (FBDSes) are specific to leucine-rich glioma-inactivated-1 (LGI1) encephalitis, and they appear in up to 70% of patients: they have a duration of less than 30 s, they have a frequency of 10–100 times per day, and they most often occur before the development of cognitive disturbance [38,43,44,51]

  • With only a dozen cases diagnosed so far, amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) autoantibodies associated with encephalitis are often accompanied by an acute to subacute onset, with the signs being dependent on the area of the brain involved, such as the limbic and cerebral encephalitis or encephalomyelitis [85,87]

Read more

Summary

Introduction

Contrary to established knowledge, a series of autoantibody-mediated seizure-associated disorders have been identified. There is limited knowledge on how autoantibodies against the different neuronal surface proteins could determine such a variety of diverse clinical patterns, and the identification of new autoantibodies is one of the state-of-art methods used in elucidating the pathogenesis and classification of these seizure-associated disorders. Antibody binding, internalization, and damage of the specific surface antigens, together with the activation of complements, are designated factors involved in physio-pathological mechanisms [3]. At this point, there is a demonstrated need to extend the knowledge on the pathophysiology of these conditions and to improve diagnostic methods, which will subsequently have obvious positive consequences on more effective and precise therapies. The symptoms relate mainly to the disruption of the target antigen

General Features of Autoantibodies against Surface Neuronal Proteins
LGI1 and CASPR2
GABABR
Seizure Disorders Associated with Surface Neuronal Protein Autoantibodies
LGI1 and CASPR2 Autoantibodies
NMDAR Autoantibodies
GABABR Autoantibodies
AMPAR Autoantibodies
Surface Neuronal Proteins and Animals
Findings
Conclusions

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.